Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN

Abstract Background Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by relapsing and remitting inflammation that leads to progressive bowel damage. Despite advances in medical treatment for CD, many patients require surgical intervention. Most studies of surgery rates are...

Full description

Bibliographic Details
Main Authors: Michelle Vu, Sabyasachi Ghosh, Kandavadivu Umashankar, Laura Weber, Christina Landis, Ninfa Candela, Benjamin Chastek
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Gastroenterology
Subjects:
Crohn’s disease
Inflammatory bowel disease
Biologic
Vedolizumab
Ustekinumab
Surgery
Online Access:https://doi.org/10.1186/s12876-023-02723-5

Similar Items

Similar Items